Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial.
Niyomnaitham S, Toh ZQ, Licciardi PV, Wongprompitak P, Srisutthisamphan K, Copeland KK, Chokephaibulkit K. Niyomnaitham S, et al. Among authors: srisutthisamphan k. J Infect. 2022 Oct;85(4):436-480. doi: 10.1016/j.jinf.2022.06.014. Epub 2022 Jun 18. J Infect. 2022. PMID: 35728642 Free PMC article. Clinical Trial. No abstract available.
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
Niyomnaitham S, Quan Toh Z, Wongprompitak P, Jansarikit L, Srisutthisamphan K, Sapsutthipas S, Jantraphakorn Y, Mingngamsup N, Licciardi PV, Chokephaibulkit K. Niyomnaitham S, et al. Among authors: srisutthisamphan k. Hum Vaccin Immunother. 2022 Nov 30;18(6):2091865. doi: 10.1080/21645515.2022.2091865. Epub 2022 Jul 11. Hum Vaccin Immunother. 2022. PMID: 35816053 Free PMC article. Clinical Trial.
Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations.
Niyomnaitham S, Atakulreka S, Wongprompitak P, Copeland KK, Toh ZQ, Licciardi PV, Srisutthisamphan K, Jansarikit L, Chokephaibulkit K. Niyomnaitham S, et al. Among authors: srisutthisamphan k. Front Immunol. 2023 Jan 17;13:1080791. doi: 10.3389/fimmu.2022.1080791. eCollection 2022. Front Immunol. 2023. PMID: 36733395 Free PMC article. Clinical Trial.
Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults.
Assantachai P, Niyomnaitham S, Chatthanawaree W, Intalapaporn S, Muangpaisan W, Phannarus H, Saichompoo RB, Sura-Amonrattana U, Wongprompitak P, Toh ZQ, Licciardi PV, Srisutthisamphan K, Chokephaibulkit K. Assantachai P, et al. Among authors: srisutthisamphan k. J Infect Dis. 2023 Oct 3;228(7):868-877. doi: 10.1093/infdis/jiad133. J Infect Dis. 2023. PMID: 37141388 Free PMC article. Clinical Trial.
The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series.
Angkasekwinai N, Niyomnaitham S, Sewatanon J, Phumiamorn S, Sukapirom K, Senawong S, Toh ZQ, Umrod P, Somporn T, Chumpol S, Ritthitham K, Jantraphakorn Y, Srisutthisamphan K, Chokephaibulkit K. Angkasekwinai N, et al. Among authors: srisutthisamphan k. Asian Pac J Allergy Immunol. 2023 Jul 16. doi: 10.12932/AP-160123-1533. Online ahead of print. Asian Pac J Allergy Immunol. 2023. PMID: 37466962 Free article.
Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
Wittawatmongkol O, Bunjoungmanee P, Kosalaraksa P, Laoprasopwattana K, Boonsathorn S, Chantasrisawad N, Sudjaritruk T, Niyomnaitham S, Senawong S, Srisutthisamphan K, Quan Toh Z, Rungmaitree S, Nanthapisal S, Phanthanawiboon S, Khantee P, Techasaensiri C, Hirankarn N, Pangprasertkul S, Chokephaibulkit K. Wittawatmongkol O, et al. Among authors: srisutthisamphan k. Vaccine. 2023 Sep 15;41(40):5834-5840. doi: 10.1016/j.vaccine.2023.08.021. Epub 2023 Aug 14. Vaccine. 2023. PMID: 37586956 Free article. Clinical Trial.
Impact of mAb-induced A475V substitution on viral fitness and antibody neutralization of SARS-CoV-2 omicron variants in the presence of monoclonal antibodies and human convalescent sera.
Viriyakitkosol R, Wanitchang A, Srisutthisamphan K, Saenboonreung J, Boonkrai C, Pisitkun T, Jongkaewwattana A. Viriyakitkosol R, et al. Among authors: srisutthisamphan k. Front Immunol. 2023 Aug 1;14:1219546. doi: 10.3389/fimmu.2023.1219546. eCollection 2023. Front Immunol. 2023. PMID: 37593745 Free PMC article.
The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine.
Mahasirimongkol S, Khunphon A, Kwangsukstid O, Sapsutthipas S, Wichaidit M, Rojanawiwat A, Wichuckchinda N, Puangtubtim W, Pimpapai W, Soonthorncharttrawat S, Wanitchang A, Jongkaewwattana A, Srisutthisamphan K, Phainupong D, Thawong N, Piboonsiri P, Sawaengdee W, Somsaard T, Ritthitham K, Chumpol S, Pinyosukhee N, Wichajarn R, Dhepakson P, Iamsirithaworn S, Phumiamorn S. Mahasirimongkol S, et al. Among authors: srisutthisamphan k. Vaccines (Basel). 2022 Mar 30;10(4):536. doi: 10.3390/vaccines10040536. Vaccines (Basel). 2022. PMID: 35455285 Free PMC article.
Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N, Manopwisedjaroen S, Rattanapisit K, Panapitakkul C, Kemthong T, Suttisan N, Srisutthisamphan K, Malaivijitnond S, Thitithanyanont A, Jongkaewwattana A, Shanmugaraj B, Phoolcharoen W. Khorattanakulchai N, et al. Among authors: srisutthisamphan k. J Med Virol. 2022 Sep;94(9):4265-4276. doi: 10.1002/jmv.27881. Epub 2022 Jun 1. J Med Virol. 2022. PMID: 35615895 Free PMC article.
26 results